|
1
|
Patel T: Increasing incidence and
mortality of primary intrahepatic cholangiocarcinoma in the United
States. Hepatology. 33:1353–1357. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xiao J, Zhu J, Liu Z, Wan R, Li Y and Xiao
W: Role of surgical treatment for hepatolithiasis-associated
intrahepatic cholangio-carcinoma: A retrospective study in a single
institution. J Cancer Res Ther. 13:756–760. 2017. View Article : Google Scholar
|
|
3
|
Arbelaiz A, Azkargorta M, Krawczyk M,
Santos-Laso A, Lapitz A, Perugorria MJ, Erice O, Gonzalez E,
Jimenez-Agüero R, Lacasta A, et al: Serum extracellular vesicles
contain protein biomarkers for primary sclerosing cholangitis and
cholangiocar-cinoma. Hepatology. 66:1125–1143. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim TS, Pak JH, Kim JB and Bahk YY:
Clonorchis sinensis, an oriental liver fluke, as a human biological
agent of cholangiocar-cinoma: A brief review. BMB Rep. 49:590–597.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jang MH, Lee YJ and Kim H: Intrahepatic
cholangiocarcinoma arising in Caroli's disease. Clin Mol Hepatol.
20:402–405. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shi Y, Jiang Z, Yang Y, Zheng P, Wei H,
Lin Y, Lv G and Yang Q: Clonorchis sinensis infection and
co-infection with the hepatitis B virus are important factors
associated with cholan-giocarcinoma and hepatocellular carcinoma.
Parasitol Res. 116:2645–2649. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Blechacz B: Cholangiocarcinoma: Current
knowledge and new developments. Gut Liver. 11:13–26. 2017.
View Article : Google Scholar :
|
|
8
|
Razumilava N and Gores GJ:
Cholangiocarcinoma. Lancet. 383:2168–2179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang H, Yang T, Wu M and Shen F:
Intrahepatic cholangio-carcinoma: Epidemiology, risk factors,
diagnosis and surgical management. Cancer Lett. 379:198–205. 2016.
View Article : Google Scholar
|
|
10
|
Ng K, Meyerhardt JA, Chan AT, Sato K, Chan
JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB III, Schaefer PL,
et al: Aspirin and COX-2 inhibitor use in patients with stage III
colon cancer. J Natl Cancer Inst. 107:3452014.PubMed/NCBI
|
|
11
|
Barron TI, Flahavan EM, Sharp L, Bennett K
and Visvanathan K: Recent prediagnostic aspirin use, lymph node
involvement, and 5-year mortality in women with stage I-III breast
cancer: A nationwide population-based cohort study. Cancer Res.
74:4065–4077. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Simon TG, Ma Y, Ludvigsson JF, Chong DQ,
Giovannucci EL, Fuchs CS, Meyerhardt JA, Corey KE, Chung RT, Zhang
X and Chan AT: Association between aspirin use and risk of
hepatocellular carcinoma. JAMA Oncol. 4:1683–1690. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Choi J, Ghoz HM, Peeraphatdit T, Baichoo
E, Addissie BD, Harmsen WS, Therneau TM, Olson JE, Chaiteerakij R
and Roberts LR: Aspirin use and the risk of cholangiocarcinoma.
Hepatology. 64:785–796. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guenzle J, Garrelfs NWC, Goeldner JM and
Weyerbrock A: Cyclooxygenase (COX) inhibition by acetyl salicylic
acid (ASA) enhances antitumor effects of nitric oxide in
glioblastoma in vitro. Mol Neurobiol. 56:6046–6055. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Henry WS, Laszewski T, Tsang T, Beca F,
Beck AH, McAllister SS and Toker A: Aspirin suppresses growth in
PI3K-mutant breast cancer by activating AMPK and inhibiting mTORC1
signaling. Cancer Res. 77:790–801. 2017. View Article : Google Scholar :
|
|
16
|
Liu YX, Feng JY, Sun MM, Liu BW, Yang G,
Bu YN, Zhao M, Wang TJ, Zhang WY, Yuan HF and Zhang XD: Aspirin
inhibits the proliferation of hepatoma cells through controlling
GLUT1-mediated glucose metabolism. Acta Pharmacol Sin. 40:122–132.
2019. View Article : Google Scholar :
|
|
17
|
Huang Z, Fang W, Liu W, Wang L, Liu B and
Liu S and Liu S: Aspirin induces Beclin-1-dependent autophagy of
human hepatocellular carcinoma cell. Eur J Pharmacol. 823:58–64.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Raza H, John A and Benedict S:
Acetylsalicylic acid-induced oxidative stress, cell cycle arrest,
apoptosis and mitochondrial dysfunction in human hepatoma HepG2
cells. Eur J Pharmacol. 668:15–24. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pavlovic N, Rani B, Gerwins P and
Heindryckx F: Platelets as key factors in hepatocellular carcinoma.
Cancers (Basel). 11:10222019. View Article : Google Scholar
|
|
20
|
Malehmir M, Pfister D, Gallage S,
Szydlowska M, Inverso D, Kotsiliti E, Leone V, Peiseler M,
Surewaard BGJ, Rath D, et al: Platelet GPIbα is a mediator and
potential interventional target for NASH and subsequent liver
cancer. Nat Med. 25:641–655. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
22
|
Kanehisa M, Sato Y, Furumichi M, Morishima
K and Tanabe M: New approach for understanding genome variations in
KEGG. Nucleic Acids Res. 47:D590–D595. 2019. View Article : Google Scholar :
|
|
23
|
Vlachos IS, Zagganas K, Paraskevopoulou
MD, Georgakilas G, Karagkouni D, Vergoulis T, Dalamagas T and
Hatzigeorgiou AG: DIANA-miRPath v3.0: Deciphering microRNA function
with experimental support. Nucleic Acids Res. 43:W460–W466. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cho S, Jang I, Jun Y, Yoon S, Ko M, Kwon
Y, Choi I, Chang H, Ryu D, Lee B, et al: MiRGator v3.0: A microRNA
portal for deep sequencing, expression profiling and mRNA
targeting. Nucleic Acids Res. 41(Database issue): D252–D257. 2013.
View Article : Google Scholar :
|
|
25
|
Huang HY, Lin YC, Li J, Huang KY, Shrestha
S, Hong HC, Tang Y, Chen YG, Jin CN, Yu Y, et al: miRTarBase 2020:
Updates to the experimentally validated microRNA-target
inter-action database. Nucleic Acids Res. 48:D148–D154. 2020.
|
|
26
|
Pietenpol JA and Stewart ZA: Cell cycle
checkpoint signaling: Cell cycle arrest versus apoptosis.
Toxicology. 181-182:475–481. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wan P, Chi X, Du Q, Luo J, Cui X, Dong K,
Bing Y, Heres C and Geller DA: miR-383 promotes cholangiocarcinoma
cell proliferation, migration, and invasion through targeting IRF1.
J Cell Biochem. 119:9720–9729. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mansini AP, Lorenzo Pisarello MJ, Thelen
KM, Cruz-Reyes M, Peixoto E, Jin S, Howard BN, Trussoni CE, Gajdos
GB, LaRusso NF, et al: MicroRNA (miR)-433 and miR-22 dysregulations
induce histone-deacetylase-6 overexpression and ciliary loss in
cholangiocarcinoma. Hepatology. 68:561–573. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li H, Zhou ZQ, Yang ZR, Tong DN, Guan J,
Shi BJ, Nie J, Ding XT, Li B, Zhou GW and Zhang ZY: MicroRNA-191
acts as a tumor promoter by modulating the TET1-p53 pathway in
intrahepatic cholangiocarcinoma. Hepatology. 66:136–151. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li L, Piontek K, Ishida M, Fausther M,
Dranoff JA, Fu R, Mezey E, Gould SJ, Fordjour FK, Meltzer SJ, et
al: Extracellular vesicles carry microRNA-195 to intrahepatic
cholangiocarcinoma and improve survival in a rat model. Hepatology.
65:501–514. 2017. View Article : Google Scholar
|
|
31
|
Kitdumrongthum S, Metheetrairut C,
Charoensawan V, Ounjai P, Janpipatkul K, Panvongsa W,
Weerachayaphorn J, Piyachaturawat P and Chairoungdua A:
Dysregulated microRNA expression profiles in cholangiocarcinoma
cell-derived exosomes. Life Sci. 210:65–75. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Palumbo T, Poultsides GA, Kouraklis G,
Liakakos T, Drakaki A, Peros G, Hatziapostolou M and Iliopoulos D:
A functional microRNA library screen reveals miR-410 as a novel
anti-apoptotic regulator of cholangiocarcinoma. BMC Cancer.
16:3532016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lampis A, Carotenuto P, Vlachogiannis G,
Cascione L, Hedayat S, Burke R, Clarke P, Bosma E, Simbolo M,
Scarpa A, et al: MIR21 drives resistance to heat shock protein 90
inhibition in cholangio-carcinoma. Gastroenterology.
154:1066–1079.e5. 2018. View Article : Google Scholar
|
|
34
|
Li J, Gao B, Huang Z, Duan T, Li D, Zhang
S, Zhao Y, Liu L, Wang Q, Chen Z and Cheng K: Prognostic
significance of microRNA-203 in cholangiocarcinoma. Int J Clin Exp
Pathol. 8:9512–9516. 2015.PubMed/NCBI
|
|
35
|
Wang J, Xie C, Pan S, Liang Y, Han J, Lan
Y, Sun J, Li K, Sun B, Yang G, et al: N-myc downstream-regulated
gene 2 inhibits human cholangiocarcinoma progression and is
regulated by leukemia inhibitory factor/MicroRNA-181c negative
feedback pathway. Hepatology. 64:1606–1622. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Utaijaratrasmi P, Vaeteewoottacharn K,
Tsunematsu T, Jamjantra P, Wongkham S, Pairojkul C, Khuntikeo N,
Ishimaru N, Sirivatanauksorn Y, Pongpaibul A, et al: The
microRNA-15a-PAI-2 axis in cholangiocarcinoma-associated
fibroblasts promotes migration of cancer cells. Mol Cancer.
17:102018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Han YL, Yin JJ and Cong JJ: Downregulation
of microRNA-193-3p inhibits the progression of intrahepatic
cholangiocarcinoma cells by upregulating TGFBR3. Exp Ther Med.
15:4508–4514. 2018.PubMed/NCBI
|
|
38
|
Han Y, Meng F, Venter J, Wu N, Wan Y,
Standeford H, Francis H, Meininger C, Greene J Jr, Trzeciakowski
JP, et al: miR-34a-dependent overexpression of Per1 decreases
cholangiocarcinoma growth. J Hepatol. 64:1295–1304. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li Q, Xia X, Ji J, Ma J, Tao L, Mo L and
Chen W: MiR-199a-3p enhances cisplatin sensitivity of
cholangiocarcinoma cells by inhibiting mTOR signaling pathway and
expression of MDR1. Oncotarget. 8:33621–33630. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang R, Chen Y, Tang C, Li H, Wang B, Yan
Q, Hu J and Zou S: MicroRNA-144 suppresses cholangiocarcinoma cell
proliferation and invasion through targeting platelet activating
factor acetylhydrolase isoform 1b. BMC Cancer. 14:9172014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zu C, Liu S, Cao W, Liu Z, Qiang H, Li Y,
Cheng C, Ji L and Li J and Li J: MiR-590-3p suppresses
epithelial-mesenchymal tran-sition in intrahepatic
cholangiocarcinoma by inhibiting SIP1 expression. Oncotarget.
8:34698–34708. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Deng G, Teng Y, Huang F, Nie W, Zhu L,
Huang W and Xu H: MicroRNA-101 inhibits the migration and invasion
of intrahe-patic cholangiocarcinoma cells via direct suppression of
vascular endothelial growth factor-C. Mol Med Rep. 12:7079–7085.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fan F, Lu J, Yu W, Zhang Y, Xu S, Pang L
and Zhu B: MicroRNA-26b-5p regulates cell proliferation, invasion
and metastasis in human intrahepatic cholangiocarcinoma by
targeting S100A7. Oncol Lett. 15:386–392. 2018.PubMed/NCBI
|
|
44
|
Ehrlich L, Hall C, Venter J, Dostal D,
Bernuzzi F, Invernizzi P, Meng F, Trzeciakowski JP, Zhou T,
Standeford H, et al: miR-24 inhibition increases menin expression
and decreases cholangio-carcinoma proliferation. Am J Pathol.
187:570–580. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu N, Jiang F, He TL, Zhang JK, Zhao J,
Wang C, Jiang GX, Cao LP, Kang PC, Zhong XY, et al: The roles of
MicroRNA-122 overexpression in inhibiting proliferation and
invasion and stimulating apoptosis of human cholangiocarcinoma
cells. miR-24 inhibition increases menin expression and decreases
cholangio-carcinoma proliferation. Sci Rep. 5:165662015. View Article : Google Scholar
|
|
46
|
Wang P and Lv L: miR-26a induced the
suppression of tumor growth of cholangiocarcinoma via KRT19
approach. Oncotarget. 7:81367–81376. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chang W, Wang Y, Li W, Shi L and Geng Z:
MicroRNA-551b-3p inhibits tumour growth of human cholangiocarcinoma
by targeting Cyclin D1. J Cell Mol Med. 23:4945–4954. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Rizvi S and Gores GJ: Pathogenesis,
diagnosis, and management of cholangiocarcinoma. Gastroenterology.
145:1215–1229. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Petrick JL, Sahasrabuddhe VV, Chan AT,
Alavanja MC, Beane-Freeman LE, Buring JE, Chen J, Chong DQ,
Freedman ND, Fuchs CS, et al: NSAID use and risk of hepatocellular
carcinoma and intrahepatic cholangiocarcinoma: The liver cancer
pooling project. Cancer Prev Res (Phila). 8:1156–1162. 2015.
View Article : Google Scholar
|
|
50
|
Dovizio M, Bruno A, Tacconelli S and
Patrignani P: Mode of action of aspirin as a chemopreventive agent.
Recent Results Cancer Res. 191:39–65. 2013. View Article : Google Scholar
|
|
51
|
Masaki T, Shiratori Y, Rengifo W, Igarashi
K, Yamagata M, Kurokohchi K, Uchida N, Miyauchi Y, Yoshiji H,
Watanabe S, et al: Cyclins and cyclin-dependent kinases:
Comparative study of hepatocellular carcinoma versus cirrhosis.
Hepatology. 37:534–543. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang X, Feng H, Li Z, Guo J and Li M:
Aspirin is involved in the cell cycle arrest, apoptosis, cell
migration, and invasion of oral squamous cell carcinoma. Int J Mol
Sci. 19:20292018. View Article : Google Scholar :
|
|
53
|
Pozzoli G, Marei HE, Althani A, Boninsegna
A, Casalbore P, Marlier LNJL, Lanzilli G, Zonfrillo M, Petrucci G,
Rocca B, et al: Aspirin inhibits cancer stem cells properties and
growth of glio-blastoma multiforme through Rb1 pathway modulation.
J Cell Physiol. Jan 30–2019.Epub ahead of print. View Article : Google Scholar
|
|
54
|
Hossain MA, Kim DH, Jang JY, Kang YJ, Yoon
JH, Moon JO, Chung HY, Kim GY, Choi YH, Copple BL and Kim ND:
Aspirin induces apoptosis in vitro and inhibits tumor growth of
human hepatocellular carcinoma cells in a nude mouse xenograft
model. Int J Oncol. 40:1298–1304. 2012. View Article : Google Scholar
|
|
55
|
Choi BH, Chakraborty G, Baek K and Yoon
HS: Aspirin-induced Bcl-2 translocation and its phosphorylation in
the nucleus trigger apoptosis in breast cancer cells. Exp Mol Med.
45:e472013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lu TX and Rothenberg ME: MicroRNA. J
Allergy Clin Immunol. 141:1202–1207. 2018. View Article : Google Scholar :
|
|
57
|
Paliouras AR, Monteverde T and Garofalo M:
Oncogene-induced regulation of microRNA expression: Implications
for cancer initiation, progression and therapy. Cancer Lett.
421:152–160. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Lu G and Zhang Y: MicroRNA-340-5p
suppresses non-small cell lung cancer cell growth and metastasis by
targeting ZNF503. Cell Mol Biol Lett. 24:342019. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Rongxin S, Pengfei L, Li S, Xiaochen J and
Yihe H: MicroRNA-340-5p suppresses osteosarcoma development by
down-regulating the Wnt/β-catenin signaling pathway via targeting
the STAT3 gene. Eur Rev Med Pharmacol Sci. 23:982–991.
2019.PubMed/NCBI
|
|
60
|
Yue W, Zheng X, Lin Y, Yang CS, Xu Q,
Carpizo D, Huang H, DiPaola RS and Tan XL: Metformin combined with
aspirin significantly inhibit pancreatic cancer cell growth in
vitro and in vivo by suppressing anti-apoptotic proteins Mcl-1 and
Bcl-2. Oncotarget. 6:21208–21224. 2015. View Article : Google Scholar : PubMed/NCBI
|
